Study Finds Nirsevimab Protects Infants Against Hospitalization For RSV, PICU Admissions, And Mechanical Ventilation

MedPage Today (7/10, Kahn) reports, “The monoclonal antibody nirsevimab (Beyfortus) protected young infants against hospitalization for respiratory syncytial virus (RSV), pediatric intensive care unit (PICU) admissions, and mechanical ventilation, according to the French prospective ENVIE study.” Researchers found that “in a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis...in infants younger than 12 months of age.” The findings were published in the New England Journal of Medicine. Also reporting is Healio (7/10, Weldon).